According to our observations, Chb‐M' was a novel drug candidate that enables the CROX approach, consistently inactivating the ErbB2/HER2 signaling pathway, and is effective on several HER2‐positive gastric cancer cell lines [17]. The gene discussed is ERBB2; the disease is gastric cancer.